To conclude, the future design of novel lung cancer therapies should consider polarization of macrophage to M1 phenotype through exogenous upregulation of miR-155 or miR-1207-5p, suppression of miR-21, or miR-103a, inhibition of IL-10 and agonist of CD47. This evidence concerns the gene CD47 and lung cancer.